AbbVie Maintains Xeljanz Safety Concerns Don’t Spill Over To Rinvoq

Responding to Pfizer post-marketing data indicating risk for CV events or cancer in patients taking Xeljanz, AbbVie tells Q4 earnings call that a more selective JAK inhibitor like Rinvoq will offer better safety.

4th quarter computer key on key board
AbbVie's Q4 revenues came in strong despite some pandemic impact on the cancer franchise

While reporting strong fourth quarter 2020 financials, AbbVie Inc. stressed during its 3 February earnings call that its JAK1 inhibitor Rinvoq likely will not present the same safety issues that a post-approval study showed for Pfizer Inc.’s JAK inhibitor Xeljanz. Company president Michael Severino said safety data compiled from Rinvoq’s use in rheumatoid arthritis to date shows no more than the expected level of major adverse cardiovascular events or malignancies.

On 27 January, Pfizer reported that a Phase IV study of Xeljanz (tofacitinib) required by the US Food and Drug...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.